Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
ACAD
ACADIA Pharmaceuticals Inc.
DAYBUE (trofinetide) and ACP-101 intranasal carbetocin are peptide therapeutics, supporting a peptide therapeutics business.
|
$3.75B |
$22.16
+4.31%
|
|
LIVN
LivaNova PLC
Directly manufactures/distributes Neuromodulation Devices, including VNS Therapy and proximal hypoglossal nerve stimulation systems.
|
$3.67B |
$67.12
+3.25%
|
|
TWST
Twist Bioscience Corporation
Twist's antibody libraries for drug discovery align with the Antibody Discovery Platform investable theme.
|
$3.66B |
$59.79
+6.33%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$3.65B |
$40.77
+3.10%
|
|
EWTX
Edgewise Therapeutics, Inc.
Edgewise's lead programs sevasemten and EDG-7500 are orally administered small-molecule therapeutics, i.e., an oral small molecule therapeutics platform.
|
$3.65B |
$34.44
+3.99%
|
|
UCTT
Ultra Clean Holdings, Inc.
Provides laboratory testing and advisory services relevant to semiconductor manufacturing cleanliness and optimization.
|
$3.61B |
$79.51
+4.02%
|
|
TNGX
Tango Therapeutics, Inc.
Directly develops oncology therapies (biotech) targeting genetically defined cancers, aligning with Biotech - Oncology.
|
$3.59B |
$26.64
+6.37%
|
|
SWTX
SpringWorks Therapeutics, Inc.
SpringWorks specializes in oncology therapies using targeted small-molecule modalities (nirogacestat and mirdametinib).
|
$3.52B |
$46.99
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$3.43B |
$39.46
-4.69%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
Kiniksa's core clinical focus centers on immunology therapeutics, driven by ARCALYST and its inflammatory disease pipeline.
|
$3.40B |
$44.95
-0.81%
|
|
SXI
Standex International Corporation
Specialty diagnostic/temperature-controlled healthcare equipment in the Scientific segment.
|
$3.37B |
$278.84
+2.94%
|
|
AMED
Amedisys, Inc.
Direct provision of Home Health and Hospice services across multiple centers.
|
$3.31B |
$100.99
|
|
TXG
10x Genomics, Inc.
TXG directly manufactures and sells diagnostic instrument platforms for single-cell and spatial biology workflows.
|
$3.30B |
$26.11
+3.45%
|
|
BKD
Brookdale Senior Living Inc.
Brookdale provides healthcare services and facilities through its senior living communities, including care delivery and facility management.
|
$3.27B |
$13.73
-2.83%
|
|
CPRX
Catalyst Pharmaceuticals, Inc.
CPRX directly develops and sells oral small molecule therapeutics (FIRDAPSE, AGAMREE, FYCOMPA).
|
$3.23B |
$26.30
+1.58%
|
|
ICUI
ICU Medical, Inc.
Infusion Systems is a major product line (Plum pumps, Medfusion/CADD integration) central to ICU Medical's revenue.
|
$3.21B |
$129.91
+3.07%
|
|
BEAM
Beam Therapeutics Inc.
Beam's core offering is a base editing gene therapy platform (DNA editing to correct disease-causing mutations).
|
$3.19B |
$31.38
+3.46%
|
|
ATS
ATS Corporation
ATS-related offerings intersect with Medical Devices & Biometrics via automated production of regulated devices.
|
$3.17B |
$32.75
+4.63%
|
|
ITGR
Integer Holdings Corporation
Integer is a contract development and manufacturing organization (CDMO) for medical devices, directly providing design, development and manufacturing services to OEMs.
|
$3.16B |
$90.24
+2.12%
|
|
GPCR
Structure Therapeutics Inc.
Company focuses on developing oral small-molecule GPCR-targeted therapeutics, including lead GLP-1R agonist and other oral GPCR modulators.
|
$3.08B |
$50.73
-5.18%
|
|
DNLI
Denali Therapeutics Inc.
DNL310 and DNL126 are recombinant enzymes delivered via Denali's TransportVehicle platform, representing its core product categories.
|
$3.02B |
$20.55
-0.75%
|
|
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE topical PDE4 inhibitor targets inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$3.00B |
$24.55
+1.49%
|
|
IDYA
IDEAYA Biosciences, Inc.
IDEAYA is a biotechnology company focused on precision oncology therapies (synthetic lethality and ADCs).
|
$2.97B |
$33.89
+4.24%
|
|
PRVA
Privia Health Group, Inc.
Privia provides physician enablement, MSO and value-based care services, i.e., Healthcare Services & Facilities.
|
$2.95B |
$24.02
+2.21%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus is focused on CNS/neuropsychiatric drug development with a pipeline spanning ADHD, depression, epilepsy, and Parkinson's disease, including SPN-817, SPN-820, and SPN-443.
|
$2.95B |
$51.40
+4.43%
|
|
CON
Concentra Group Holdings Parent, Inc.
Concentra operates a nationwide network of outpatient occupational health centers and onsite employer clinics, i.e., outpatient/ASC operations.
|
$2.93B |
$22.86
+2.37%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.92B |
$20.42
+2.56%
|
|
RLAY
Relay Therapeutics, Inc.
Directly develops oncology therapies (lead asset RLY-2608) and precision medicine leveraging its platform.
|
$2.90B |
$16.77
+4.10%
|
|
HAE
Haemonetics Corporation
Haemonetics manufactures medical devices and biometrics for hospital blood management and plasma processing.
|
$2.88B |
$61.61
+2.50%
|
|
ELVN
Enliven Therapeutics, Inc.
Directly develops oncology therapeutics (small-molecule kinase inhibitors) for cancer, including lead assets ELVN-001 (BCR-ABL) and ELVN-002 (HER2).
|
$2.86B |
$48.06
+6.00%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
XDEMVY is an FDA-approved ophthalmic drug and core commercial product for Demodex blepharitis.
|
$2.85B |
$67.25
-0.69%
|
|
SLNO
Soleno Therapeutics, Inc.
Core product category: Soleno's VYKAT XR is an oral small molecule therapeutic (diazoxide choline extended-release) targeting hyperphagia in Prader-Willi Syndrome.
|
$2.83B |
$52.78
+0.40%
|
|
PBH
Prestige Consumer Healthcare Inc.
Clear Eyes is an ophthalmic over-the-counter product, fitting Ophthalmic Drugs.
|
$2.80B |
$58.06
+1.77%
|
|
SPNT
SiriusPoint Ltd.
Accident & Health lines indicate health-related insurance offerings, aligned with Health Insurance.
|
$2.72B |
$23.29
+2.69%
|
|
IRON
Disc Medicine, Inc.
Disc Medicine concentrates on rare hematologic diseases (e.g., EPP, Diamond-Blackfan anemia) by targeting iron and heme pathways, with a pipeline centered on rare-disease indications.
|
$2.71B |
$71.81
+3.39%
|
Showing page 9 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
